|Bid||112.84 x 100|
|Ask||113.55 x 800|
|Day's Range||112.55 - 113.56|
|52 Week Range||94.20 - 119.30|
|PE Ratio (TTM)||3.92|
|Expense Ratio (net)||0.47%|
CNCR ETF is up about 30% this year; here is what investors need to know about immunotherapy and the ETF (CNCR, IBB).
Healthcare sector has proven itself to be one of the most resilient sectors of the US economy. Since healthcare cannot be outsourced and represents an expense that people usually cut on last during economic downturns, investing in healthcare stocks is a good way to recession-proof your portfolio. Moreover, the sector itself is comprised of many […]
Development of a drug is a tedious, time-consuming and expensive process, with the journey of the drug from the lab to the pharmacy shelf usually taking around 12 years . Companies support their filings ...
There were some huge moves in the biotech space in the past week, with Portola Pharmaceuticals Inc (NASDAQ: PTLA ) slumping over 25 percent on perceived FDA risk after the company said the FDA may mandate ...
The number of biotech stocks posting gains outstripped those recording losses for the week. Notable among the gainers for the week were Odonate Therapeutics Inc (NASDAQ: ODT ) — which reported its financial ...
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) much like the entire stock market had a difficult two weeks. Fundamentally, TEVA stock is not cheap. TEVA stock is still close to an all-time pivot point, which is likely to hold in the long run.
With biotech stocks tumbling toward long-term levels of support, we take a closer look at how active traders will trade the bounce.
The “Fast Money” traders share their final trades for the day including Advanced Micro Devices, Square, iShares Nasdaq Biotech ETF and Facebook.